公开(公告)号：WO2018183889A1

公开(公告)日：2018-10-04

申请号：PCT/US2018/025460

申请日：2018-03-30

Applicant: POTENZA THERAPEUTICS, INC. ,  STEINER, Philipp

Inventor： STEINER, Philipp ,  NIELSON, Nels, P. ,  HICKLIN, Daniel ,  SEIDEL-DUGAN, Cynthia ,  WINSTON, William ,  BRODKIN, Heather ,  SALMERON-GARCIA, Jose-Andres ,  NIRSCHL, Christopher, James

IPC: C07K16/22 ,  C07K16/28 ,  A61K39/00

Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to TIGIT and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.

公开(公告)号：WO2013013025A2

公开(公告)日：2013-01-24

申请号：PCT/US2012047370

申请日：2012-07-19

Applicant: MEDIMMUNE LTD ,  BEDIAN VAHE ,  WANG YOUZHEN ,  FOLTZ IAN NEVIN ,  RATHANASWAMI PALANISWAMI ,  KANG JASPAL SINGH ,  KAMAL ADEEIA ,  STEINER PHILIPP

Inventor： BEDIAN VAHE ,  WANG YOUZHEN ,  FOLTZ IAN NEVIN ,  RATHANASWAMI PALANISWAMI ,  KANG JASPAL SINGH ,  KAMAL ADEEIA ,  STEINER PHILIPP

IPC: A61K39/395

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K45/06 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

Abstract: The disclosure relates to antibodies or antigen binding fragments that specifically bind to CXCR4 and inhibit the biological activity of CXCR4 and uses of such agents. More specifically the disclosure relates to fully human antibodies or antigen binding fragments directed to CXCR4 that specifically bind to CXCR4 and uses of these antibodies. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies. The disclosed antibodies (including antigen binding fragments) are useful as diagnostics and for the treatment of diseases associated with the activity and/or expression of CXCR4.

Abstract translation: 本公开涉及特异性结合CXCR4并抑制CXCR4的生物学活性的抗体或抗原结合片段以及这些试剂的用途。 更具体地，本公开涉及针对CXCR4的完全人抗体或抗原结合片段，其特异性结合CXCR4和这些抗体的用途。 本公开的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所公开的抗体（包括抗原结合片段）可用作诊断和治疗与CXCR4的活性和/或表达相关的疾病。

公开(公告)号：WO2006125821A2

公开(公告)日：2006-11-30

申请号：PCT/EP2006062628

申请日：2006-05-24

Applicant: CYTOS BIOTECHNOLOGY AG ,  EMMERLING MARCEL ,  HENNECKE FRANK ,  PFRUENDER HOLGER ,  RHIEL MARTIN ,  STEINER PHILIPP

Inventor： EMMERLING MARCEL ,  HENNECKE FRANK ,  PFRUENDER HOLGER ,  RHIEL MARTIN ,  STEINER PHILIPP

CPC classification number: C07K14/005 ,  A61K2039/5256 ,  A61K2039/5258 ,  C12N7/00 ,  C12N2795/00023 ,  C12N2795/00051 ,  C12N2795/10051 ,  C12N2795/10061 ,  C12N2795/18022 ,  C12N2795/18052

Abstract: This invention provides a robust fermentation process for the expression of a capsid protein of a bacteriophage which is forming a VLP by self-assembly, wherein the process is scalable to a commercial production scale and wherein the expression rate of the capsid protein is controlled to obtain improved yield of soluble capsid protein. This is achieved by combining the advantages of fed-batch culture and of lactose induced expression systems with specific process parameters providing improved repression of the promoter during the growth phase and high plasmid retention throughout the process.

Abstract translation: 本发明提供了用于通过自组装形成VLP的噬菌体的衣壳蛋白的表达的鲁棒发酵方法，其中该方法可扩展到商业生产规模，并且其中控制衣壳蛋白的表达速率以获得 提高可溶性衣壳蛋白的产量。 这是通过将补料分批培养和乳糖诱导表达系统的优点与具体工艺参数相结合来实现的，其提供了在生长阶段改进的启动子抑制以及整个过程中的高质粒保留。

公开(公告)号：WO2013013025A3

公开(公告)日：2013-01-24

申请号：PCT/US2012/047370

申请日：2012-07-19

Applicant: MEDIMMUNE LIMITED ,  BEDIAN, Vahe ,  WANG, Youzhen ,  FOLTZ, Ian, Nevin ,  RATHANASWAMI, Palaniswami ,  KANG, Jaspal, Singh ,  KAMAL, Adeeia ,  STEINER, Philipp

Inventor： BEDIAN, Vahe ,  WANG, Youzhen ,  FOLTZ, Ian, Nevin ,  RATHANASWAMI, Palaniswami ,  KANG, Jaspal, Singh ,  KAMAL, Adeeia ,  STEINER, Philipp

IPC: A61K39/395

Abstract: The disclosure relates to antibodies or antigen binding fragments that specifically bind to CXCR4 and inhibit the biological activity of CXCR4 and uses of such agents. More specifically the disclosure relates to fully human antibodies or antigen binding fragments directed to CXCR4 that specifically bind to CXCR4 and uses of these antibodies. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies. The disclosed antibodies (including antigen binding fragments) are useful as diagnostics and for the treatment of diseases associated with the activity and/or expression of CXCR4.

公开(公告)号：WO2011133576A1

公开(公告)日：2011-10-27

申请号：PCT/US2011/033090

申请日：2011-04-19

Applicant: BE INTELLECTUAL PROPERTY, INC. ,  COOK, Donald, F. ,  HARRINGTON, Liberty, D. ,  STEINER, Philipp ,  BRAUER, Robert, K.

Inventor： COOK, Donald, F. ,  HARRINGTON, Liberty, D. ,  STEINER, Philipp ,  BRAUER, Robert, K.

IPC: B64D11/02

CPC classification number: B64C1/10 ,  B64D11/02 ,  B64D11/06 ,  B64D11/064 ,  B64F5/00 ,  Y02T50/46

Abstract: A lavatory for an aircraft cabin includes a wall having a forward wall portion disposed immediately aft of and substantially conforming to an exterior aft surface of an aircraft cabin structure, such as a passenger seat, that is substantially not flat in a vertical plane. The forward wall portion includes a forward projection over an aft portion of the adjacent passenger seat. The forward wall portion can define a secondary space in the interior lavatory space, which can provide an amenity stowage space, and can include design elements providing visual space.

Abstract translation: 飞机机舱的洗手间包括壁，其具有立即在垂直平面中基本上不平坦的飞机机舱结构（例如乘客座椅）的后部立即后方并基本上配合的前壁部分。 前壁部分包括在相邻乘客座椅的后部之上的向前突出部。 前壁部分可以在内部厕所空间中限定二次空间，其可以提供舒适的装载空间，并且可以包括提供视觉空间的设计元件。

公开(公告)号：WO2006125821A3

公开(公告)日：2006-11-30

申请号：PCT/EP2006/062628

申请日：2006-05-24

Applicant: CYTOS BIOTECHNOLOGY AG ,  EMMERLING, Marcel ,  HENNECKE, Frank ,  PFRÜNDER, Holger ,  RHIEL, Martin ,  STEINER, Philipp

Inventor： EMMERLING, Marcel ,  HENNECKE, Frank ,  PFRÜNDER, Holger ,  RHIEL, Martin ,  STEINER, Philipp

IPC: C12N7/02 ,  C12P21/02

Abstract: This invention provides a robust fermentation process for the expression of a capsid protein of a bacteriophage which is forming a VLP by self-assembly, wherein the process is scalable to a commercial production scale and wherein the expression rate of the capsid protein is controlled to obtain improved yield of soluble capsid protein. This is achieved by combining the advantages of fed-batch culture and of lactose induced expression systems with specific process parameters providing improved repression of the promoter during the growth phase and high plasmid retention throughout the process.